Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors ; volume:22 ; number:1 ; day:10 ; month:12 ; year:2024 ; pages:24-39 ; date:1.2025
Cellular & molecular immunology ; 22, Heft 1 (10.12.2024), 24-39, 1.2025
- Creator
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41423-024-01245-8
- URN
-
urn:nbn:de:101:1-2503052132435.252736752808
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:25 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Catanzaro, Elena
- Beltrán-Visiedo, Manuel
- Galluzzi, Lorenzo
- Krysko, Dmitri V.
- SpringerLink (Online service)
Other Objects (12)
Cancer immunotherapy beyond immune checkpoint inhibitors
Immune checkpoint inhibitors for multiple myeloma immunotherapy
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy
Immunogenicity of COVID-19 Vaccination in Melanoma Patients under Immune Checkpoint Blockade
Correction: Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy
Immune checkpoint expression on immune cells of HNSCC patients and modulation by chemoand immunotherapy
Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts
Immune checkpoint expression on immune cells of HNSCC patients and modulation by chemo- and immunotherapy
Antibody‐Conjugated Nanogel with Two Immune Checkpoint Inhibitors for Enhanced Cancer Immunotherapy
B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy
Cancer immunotherapy beyond immune checkpoint inhibitors
Immune checkpoint inhibitors for multiple myeloma immunotherapy
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy
Immunogenicity of COVID-19 Vaccination in Melanoma Patients under Immune Checkpoint Blockade
Correction: Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy
Immune checkpoint expression on immune cells of HNSCC patients and modulation by chemoand immunotherapy
Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts
Immune checkpoint expression on immune cells of HNSCC patients and modulation by chemo- and immunotherapy
Antibody‐Conjugated Nanogel with Two Immune Checkpoint Inhibitors for Enhanced Cancer Immunotherapy
B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy
Cancer immunotherapy beyond immune checkpoint inhibitors
Immune checkpoint inhibitors for multiple myeloma immunotherapy
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy
Immunogenicity of COVID-19 Vaccination in Melanoma Patients under Immune Checkpoint Blockade
Correction: Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy
Immune checkpoint expression on immune cells of HNSCC patients and modulation by chemoand immunotherapy
Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts
Immune checkpoint expression on immune cells of HNSCC patients and modulation by chemo- and immunotherapy
Antibody‐Conjugated Nanogel with Two Immune Checkpoint Inhibitors for Enhanced Cancer Immunotherapy